Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.70 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1370613 | 0.90 | PTGDR2 (0.57) | PTGDR2 | |
| SCHEMBL1366789 | 0.85 | PTGDR2 (0.73) | PTGDR2 | |
| SCHEMBL1369878 | 0.84 | PTGDR2 (0.70) | PTGDR2FFAR1 | |
| SCHEMBL1368832 | 0.83 | PTGDR2 (0.68) | PTGDR2 | |
| SCHEMBL1370449 | 0.83 | PTGDR2 (0.68) | PTGDR2 | |
| SCHEMBL1369865 | 0.83 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL1367421 | 0.80 | PTGDR2 (0.70) | PTGDR2 | |
| SCHEMBL1367423 | 0.78 | PTGDR2 (0.44) | PTGDR2 | |
| SCHEMBL1369395 | 0.77 | PTGDR2 (0.57) | PTGDR2 | |
| SCHEMBL1369027 | 0.74 | PTGS1 (0.48) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288293-A1 | ISOQUINOLINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| EP-2377851-A1 | ISOQUINOLINE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288293-A1 | ISOQUINOLINE DERIVATIVE | HRH1, HRH2, HRH4 | PTGDR2 189/4885FFAR1 1844/4885S1PR1 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.